Adlai Nortye Ltd. America... (ANL)
NASDAQ: ANL
· Real-Time Price · USD
2.02
0.07 (3.59%)
At close: May 05, 2025, 3:50 PM
1.95
-3.70%
After-hours: May 05, 2025, 04:05 PM EDT
3.59% (1D)
| Bid | 1.95 |
| Market Cap | 21.08M |
| Revenue (ttm) | 6.49M |
| Net Income (ttm) | -54.06M |
| EPS (ttm) | -1.62 |
| PE Ratio (ttm) | -1.25 |
| Forward PE | -1.97 |
| Analyst | Buy |
| Ask | 2.05 |
| Volume | 6 |
| Avg. Volume (20D) | 14,150 |
| Open | 1.90 |
| Previous Close | 1.95 |
| Day's Range | 1.90 - 2.02 |
| 52-Week Range | 1.69 - 13.92 |
| Beta | -0.92 |
About ANL
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor mic...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 23, 2023
Employees 123
Stock Exchange NASDAQ
Ticker Symbol ANL
Website https://www.adlainortye.com
Analyst Forecast
According to 2 analyst ratings, the average rating for ANL stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 344.44% from the latest price.
Stock Forecasts
